Filters








1,271 Hits in 2.5 sec

Functional Neural Transplantation. 1994. Edited by Stephen B. Dunnett and Anders Björklund. Published by Raven Press. 603 pages. $C189.00

Barry Snow
1995 Canadian Journal of Neurological Sciences  
doi:10.1017/s0317167100040051 fatcat:uhe4rql5bbd2pfvnb7g3onjc6i

Neural Transplantation Methods. 1999. Edited by Stephen B. Dunnett, Alan A. Boulton, Glen B. Baker. Published by Humana Press. 576 pages. C$185.00 approx

Andres M. Lozano
2000 Canadian Journal of Neurological Sciences  
Edited by Stephen B. Dunnett, Alan A. Boulton, Glen B. Baker. Published by Humana Press. 576 pages. C$185.00 approx. Andres M. Lozano Toronto, Canada DISORDERS OF BRAIN AND MIND. 1998.  ...  The book edited by Dunnett, Boulton and Baker is divided into three areas. (1) The sources of cells for transplantation (2) The methods of implantation and (3) Factors in graft survival and function.  ... 
doi:10.1017/s0317167100500286 fatcat:jfuxrwa5izge7oxscacgujog6y

Acetylcholine revisited

Anders Björklund, Stephen B. Dunnett
1995 Nature  
doi:10.1038/375446a0 pmid:7777048 fatcat:mjeot6ysqresvaayln57iaqzy4

Cell therapy in Huntington's disease

Stephen B. Dunnett, Anne E. Rosser
2004 Neurotherapeutics  
Dunnett SB, Nathwani F, Björklund A. The integration and function of striatal grafts. Prog Brain Res 127:345-380, 2000. 28. Mayer E, Brown VJ, Dunnett SB, Robbins TW.  ...  Döbrössy MD, Dunnett SB. Striatal grafts alleviate deficits in response execution in a lateralised reaction time task. Brain Res Bull 47:585-593, 1998. 30. Dunnett SB.  ... 
doi:10.1007/bf03206626 fatcat:soqx3kh4hnhhbpglhfwjo3dpom

Cell therapy in Huntington's disease

Stephen B. Dunnett, Anne E. Rosser
2004 NeuroRx  
Dunnett SB, Nathwani F, Björklund A. The integration and function of striatal grafts. Prog Brain Res 127:345-380, 2000. 28. Mayer E, Brown VJ, Dunnett SB, Robbins TW.  ...  Döbrössy MD, Dunnett SB. Striatal grafts alleviate deficits in response execution in a lateralised reaction time task. Brain Res Bull 47:585-593, 1998. 30. Dunnett SB.  ... 
doi:10.1602/neurorx.1.4.394 pmid:15717043 pmcid:PMC534948 fatcat:rj23jyc4izehvlrda7cdxk4zsq

Reprogramming the diseased brain

Stephen B Dunnett, Anne E Rosser
2017 Nature Biotechnology  
Direct conversion of astrocytes to dopamine neurons in vivo offers fresh optimism for the development of improved Parkinson's therapies. A study by Rivetti di Val Cervo et al. 1 in this issue heralds an exciting advance in the rapidly developing technology for direct neural reprogramming of adult somatic cells, with clear therapeutic potential in Parkinson's disease. The team reports a combination of genes and soluble factors that induces effective, efficient and stable reprogramming of
more » ... astrocytes into midbrain-like dopamine neurons, and shows that the same four genes used in vitro reprogram astrocytes in the depths of the mouse brain. The reprogrammed neurons exhibit morphological, phenotypic and electrophysiological features of normal dopamine neurons, and alleviate spontaneous, as well as drug-induced, symptoms in parkinsonian mice. Parkinson's disease has long provided an attractive target in regenerative medicine for the development of a wide array of novel gene and cell therapies (Fig. 1) , although none yet provide a practical therapy ready for widespread adoption. One reason for the sustained interest is that conventional treatments such as dopamine-replacement drugs and deep brain stimulation confer significant therapeutic benefit even though they do not restore neuronal signalling in dopaminergic circuits or alter the course of the underlying disease. The lack of regulated specificity common to these approaches may explain the declining potency and side effects that often emerge with long-term use, but their relative efficacy also suggests that the demands on a cell-based therapy may be less challenging in Parkinson's disease than in diseases that affect more precisely organized point-to-point systems of the brain. Indeed, transplantation of dopamine-rich fetal ventral mesencephalon has proved remarkably effective at alleviating symptoms for many years in small numbers of Parkinson's disease patients 2 . These results are proof of the therapeutic potential of cell replacement for this condition. However, fetal-tissue grafting is implausible as a widespread medical treatment owing to the lack of standardization inherent in this cell source, as well as ethical concerns.
doi:10.1038/nbt.3869 pmid:28486448 fatcat:ydnp7vvrvrg3lc7udcpt5ofile

A Life Shaken: My Encounter with Parkinson's Disease

Stephen B. Dunnett
2003 Nature Medicine  
Most notable are his neurologist Stephen Reich, who is quoted extensively; his employers at the Los Angeles Times, who have been willing to promote the career of a skilled journalist while he has all the  ... 
doi:10.1038/nm0203-159 fatcat:xzi5fp3iwbawzna7veq5qqdlq4

Targeting delivery in Parkinson's disease

Ben Newland, Stephen B. Dunnett, Eilís Dowd
2016 Drug Discovery Today  
Pharmaceut Res 26 (5), 1059-1063 32 Dunnett, S.B. and Rosser, A.E. (2014) Challenges for taking primary and stem cells into clinical neurotransplantation trials for neurodegenerative disease.  ...  Lower panel (B) shows GDNF expression: (1) two days post single saline injection; (2) two days post single Lf-modified NP injection; (3) six days post single Lf-modified NP injection; (4) ten days post  ... 
doi:10.1016/j.drudis.2016.06.003 pmid:27312875 fatcat:du3podwyfzcj5caidhpancfbem

THE FUNCTIONAL ROLE OF MESOTELENCEPHALIC DOPAMINE SYSTEMS

STEPHEN B. DUNNETT, TREVOR W. ROBBINS
1992 Biological Reviews  
Rev. (1992), 67, pp. 491-518 Printed in Great Britain THE FUNCTIONAL ROLE OF MESOTELENCEPHALIC DOPAMINE SYSTEMS By STEPHEN B. DUNNETT anp TREVOR W.  ...  B. DUNNETT AND T. W.  ... 
doi:10.1111/j.1469-185x.1992.tb01191.x pmid:1361154 fatcat:u6nwwpqjarfb3gbwwthhougj3a

Neural transplants as a treatment for Alzheimer's disease?1 2

Stephen B. Dunnett
1991 Psychological Medicine  
IP address: 207.241.231.82, on 18 Jul 2018 at 22:20:51, subject to the Cambridge Core terms of use, available at STEPHEN B.  ...  DUNNETT https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0033291700029822 Downloaded from https://www.cambridge.org/core.  ... 
doi:10.1017/s0033291700029822 fatcat:7fre7gjayvddfktgq6nqxtdjxi

Functional integration of neural grafts in Parkinson's disease

Roger A Barker, Stephen B. Dunnett
1999 Nature Neuroscience  
Functional imaging in a Parkinson's patient with a neural transplant shows that the graft is still functional after ten years, and that dopamine from the graft can bind to postsynaptic sites.
doi:10.1038/15969 pmid:10570477 fatcat:if6lwffh7zc7bg3x4jvnnpyb3y

Prospects for new restorative and neuroprotective treatments in Parkinson's disease

Stephen B. Dunnett, Anders Björklund
1999 Nature  
B.  ...  (MAO-B), and dopamine transport blockers 12 .  ... 
doi:10.1038/399a032 pmid:10392578 fatcat:55td6u2emnfmxm4gghej4gkzt4

Dopamine neuron systems in the brain: an update

Anders Björklund, Stephen B. Dunnett
2007 Trends in Neurosciences  
Data compiled from Lewis and Sessack [41] for (a) and Williams and Goldman-Rakic [42] for (b).  ...  Data compiled from Lewis and Sessack [41] for (a) and Williams and Goldman-Rakic [42] for (b).  ... 
doi:10.1016/j.tins.2007.03.006 pmid:17408759 fatcat:bfrcku3huzhxblf23azwlw5iou

The staircase test of skilled reaching in mice

Alison L Baird, Alicia Meldrum, Stephen B Dunnett
2001 Brain Research Bulletin  
We here validate the test in C57BL/6J mice by (a) establishing the optimal dimensions of the apparatus, (b) comparing the effects of test parameters including sex, test duration, levels of deprivation  ...  Updated information on the staircase test is maintained on our web site at http://www.cf.ac.uk/biosi/staff/dunnett/stairtxt.html.  ...  A,B. Session length, varied between 5 and 60 min. C,D.  ... 
doi:10.1016/s0361-9230(00)00457-3 pmid:11275415 fatcat:4ihzwx22bfhsfngaiqugfxuw2q

Cognitive training modifies disease symptoms in a mouse model of Huntington's disease

Emma Yhnell, Mariah J. Lelos, Stephen B. Dunnett, Simon P. Brooks
2016 Experimental Neurology  
. * p b 0.05, ** p b 0.01, *** p b 0.001. interaction was demonstrated(Fig. 4B, Group × Genotype; F 1,24 = 1.29, p = n.s.). The Authors. Published by Elsevier Inc.  ...  Significant results are indicated, Grp = Group, Geno = Genotype, S.L. = stimulus length. * p b 0.05, ** p b 0.01, *** p b 0.001. failed to meet significance, due to the similar improvement demonstrated  ... 
doi:10.1016/j.expneurol.2016.05.008 pmid:27163546 pmcid:PMC4920669 fatcat:4ndigk5kazdexpvrd3n7p6j45e
« Previous Showing results 1 — 15 out of 1,271 results